Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm

Figures & data

Table 1 Comparison of male and female HFS and BEB patients before treatment (n=90)

Group	n	SAS score	SDS score
HFS group
Male	36	40.17±8.36	40.25±6.46
Female	54	43.56±6.10*	45.48±7.31*
BEB group
Male	33	56.45±8.75	57.90±7.93
Female	57	60.89±9.11*	60.12±8.35*

Note:

* P<0.05 vs male (Student’s t-test).

Abbreviations: BEB, benign essential blepharospasm; HFS, hemifacial spasm; SAS, self-rating anxiety scale; SDS, self-rating depression scale.

Table 2 SAS and SDS scores for HFS and BEB patients after BTX-A treatment

Group	SAS before treatment	SDS before treatment	SAS after treatment	SDS after treatment
HFS	41.25±6.35	42.25±7.57	30.12±4.35*	30.58±4.89*
BEB	58.90±10.61	58.78±9.89	38.17±3.67*	38.12±4.15*

Note:

* P<0.05 vs before treatment (Student’s t-test).

Abbreviations: BEB, benign essential blepharospasm; BTX-A, botulinum toxin type A; HFS, hemifacial spasm; SAS, self-rating anxiety scale; SDS, self-rating depression scale.